R1 RCM (NASDAQ:RCM) Rating Reiterated by Robert W. Baird

R1 RCM (NASDAQ:RCM)‘s stock had its “outperform” rating restated by investment analysts at Robert W. Baird in a research note issued on Tuesday, Benzinga reports. They currently have a $18.00 price objective on the healthcare provider’s stock. Robert W. Baird’s target price points to a potential upside of 61.73% from the stock’s current price.

Several other brokerages also recently weighed in on RCM. Morgan Stanley reaffirmed an “overweight” rating and set a $17.00 price target on shares of R1 RCM in a report on Tuesday, March 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 target price on shares of R1 RCM in a report on Tuesday. Guggenheim reduced their target price on R1 RCM from $17.00 to $15.00 and set a “buy” rating for the company in a report on Friday, April 5th. KeyCorp reissued a “sector weight” rating on shares of R1 RCM in a report on Wednesday, April 10th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $19.00 target price on shares of R1 RCM in a report on Friday, June 28th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

R1 RCM Price Performance

Shares of NASDAQ RCM opened at $11.13 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.79 and a quick ratio of 1.79. The stock has a fifty day moving average price of $12.41 and a 200 day moving average price of $11.89. R1 RCM has a 1-year low of $8.87 and a 1-year high of $18.70. The company has a market cap of $4.69 billion, a PE ratio of -139.13 and a beta of 0.85.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). R1 RCM had a negative return on equity of 1.16% and a negative net margin of 1.39%. The company had revenue of $603.90 million for the quarter, compared to analyst estimates of $612.88 million. The firm’s revenue was up 10.7% compared to the same quarter last year. Sell-side analysts forecast that R1 RCM will post -0.17 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in R1 RCM by 5.6% during the 3rd quarter. Vanguard Group Inc. now owns 17,940,792 shares of the healthcare provider’s stock worth $270,368,000 after purchasing an additional 947,310 shares in the last quarter. Capital International Investors increased its position in R1 RCM by 0.8% during the 4th quarter. Capital International Investors now owns 8,343,199 shares of the healthcare provider’s stock worth $88,188,000 after purchasing an additional 67,485 shares in the last quarter. Voss Capital LLC increased its position in R1 RCM by 553.9% during the 4th quarter. Voss Capital LLC now owns 7,125,000 shares of the healthcare provider’s stock worth $75,311,000 after purchasing an additional 6,035,340 shares in the last quarter. Polar Capital Holdings Plc increased its position in R1 RCM by 0.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 4,696,412 shares of the healthcare provider’s stock worth $70,775,000 after purchasing an additional 22,550 shares in the last quarter. Finally, Norges Bank purchased a new stake in R1 RCM during the 4th quarter worth about $42,539,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.